Taiwan - Delayed Quote TWD

PharmaEssentia Corporation (6446.TW)

514.00
+1.00
+(0.19%)
At close: May 27 at 1:30:24 PM GMT+8
Currency in TWD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
11,338,682
9,734,814
5,105,615
2,882,042
656,506
Cost of Revenue
1,346,515
1,177,225
610,544
812,288
378,856
Gross Profit
9,992,167
8,557,589
4,495,071
2,069,754
277,650
Operating Expense
7,168,394
6,821,512
6,408,465
4,097,946
3,100,058
Operating Income
2,823,773
1,736,077
-1,913,394
-2,028,192
-2,822,408
Net Non Operating Interest Income Expense
881,784
895,263
538,436
21,913
-5,339
Pretax Income
4,120,530
2,994,652
-986,934
-1,841,871
-2,810,988
Tax Provision
221,856
29,149
-363,099
-467,061
0
Net Income Common Stockholders
3,898,674
2,965,503
-623,835
-1,374,810
-2,810,988
Diluted NI Available to Com Stockholders
3,898,674
2,965,503
-623,835
-1,374,810
-2,810,988
Basic EPS
11.76
8.96
-1.93
-4.84
-10.80
Diluted EPS
11.67
8.88
-1.93
-4.84
-10.80
Basic Average Shares
331,632.25
331,100
322,479
284,207
260,166
Diluted Average Shares
334,189.78
334,052
322,479
284,207
260,166
Total Expenses
8,514,909
7,998,737
7,019,009
4,910,234
3,478,914
Net Income from Continuing & Discontinued Operation
3,898,674
2,965,503
-623,835
-1,374,810
-2,810,988
Normalized Income
3,898,674
2,965,503
-623,835
-1,374,810
-2,810,988
Interest Income
904,259
917,455
585,127
40,441
4,631
Interest Expense
22,475
22,192
46,691
18,528
9,970
Net Interest Income
881,784
895,263
538,436
21,913
-5,339
EBIT
4,143,005
3,016,844
-940,243
-1,823,343
-2,801,018
EBITDA
4,518,794
3,384,556
-671,486
-1,595,424
-2,573,937
Reconciled Cost of Revenue
1,346,515
1,177,225
610,544
812,288
378,856
Reconciled Depreciation
375,789
367,712
268,757
227,919
227,081
Net Income from Continuing Operation Net Minority Interest
3,898,674
2,965,503
-623,835
-1,374,810
-2,810,988
Normalized EBITDA
4,518,794
3,384,556
-671,486
-1,595,424
-2,573,937
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 3/11/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

6472.TW Bora Pharmaceuticals Co., LTD.
769.00
-0.77%
 
1795.TW Lotus Pharmaceutical Co., Ltd.
235.00
+3.75%
 
4746.TW Formosa Laboratories, Inc.
70.50
+0.71%
 
4123.TWO Center Laboratories, Inc.
39.70
-0.63%
 
3705.TW YungShin Global Holding Corporation
61.80
+0.65%
 
1707.TW Grape King Bio Ltd
133.50
-0.74%
 
6785.TWO Alar Pharmaceuticals Inc.
145.00
-1.36%
 
4108.TW PhytoHealth Corporation
15.15
-5.31%
 
4114.TWO Synmosa Biopharma Corporation
34.05
-0.15%
 
4105.TWO TTY Biopharm Company Limited
75.60
+0.53%